UBS Group: Raises Moderna price target from $50 to $150

Odaily News: UBS Group said it has raised its price target for Moderna (MRNA.O) from $50 to $150. Previously reported, the personalized mRNA cancer vaccine developed by Moderna in collaboration with Merck achieved significant success in a Phase 3 clinical trial for high-risk melanoma, making it the world's first mRNA cancer therapy to prove effective in a large-scale Phase 3 trial. Following the announcement, Moderna's stock price surged nearly 177% in a single day.